Mouse Anti-CD19 Recombinant Antibody (CBXC-1224) (CBMAB-C1491-CQ)

Name: Mouse Anti-CD19 Recombinant Antibody (CBXC-1224)
SKU: CBMAB-C1491-CQ
Rating: 5 (1 reviews)

See all CD19 antibodies

Compare Online Inquiry

Published Data

Mouse Anti-CD19 Recombinant Antibody (CBXC-1224) (CBMAB-C1491-CQ) in FC

Markedly induced Bregs (CD19+ CD5+ IL-10+) in the intestinal tissues, which also showed high expression of GL7 (an activation marker of lymphocytes) upon exposure to specific antigen, OVA, in culture overnight. ...View More

Zeng, H. T., Liu, Y., Zhao, M., Liu, J. Q., Jin, Q. R., Liu, Z. Q., ... & Yang, P. (2022). Modulating oxidative stress in B cells promotes immunotherapy in food allergy. Oxidative Medicine and Cellular Longevity, 2022(1), 3605977. Distributed under Open Access license CC BY 4.0, without modification.

Mouse Anti-CD19 Recombinant Antibody (CBXC-1224) (CBMAB-C1491-CQ) in FC

FACS gating procedures. Surgically removed colon tissues from a non-UC patient were used in this experiment to illustrate the FACS gating procedures. ...View More

Liu, C., Mo, L. H., Feng, B. S., Jin, Q. R., Li, Y., Lin, J., ... & Yang, P. C. (2021). Twist1 contributes to developing and sustaining corticosteroid resistance in ulcerative colitis. Theranostics, 11(16), 7797. Distributed under Open Access license CC BY 4.0, without modification.

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

CBXC-1224

Application

WB, IP, ELISA, IF

Immunogen

Amino acids 1-300 mapping at the N-terminus of CD19 of human origin.

Host Species

Mouse

Specificity

Human, Mouse, Rat

Antibody Isotype

IgG2a, κ

Clonality

Monoclonal Antibody

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Application	Note
WB	1:100-1:1,000
IP	1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)
IF(ICC)	1:50-1:500
ELISA	1:100-1:1,000

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

PBS, 0.1% gelatin

Preservative

< 0.1% sodium azide

Concentration

0.2 mg/ml

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

More Infomation

Target

Full Name

CD19 Molecule

Introduction

CD19 (CD19 Molecule) is a Protein Coding gene. Diseases associated with CD19 include Immunodeficiency, Common Variable, 3 and Common Variable Immunodeficiency. Among its related pathways are RET signaling and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. Gene Ontology (GO) annotations related to this gene include signal transducer activity, downstream of receptor.

Entrez Gene ID

930

UniProt ID

P15391

Alternative Names

CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; B-Lymphocyte Antigen CD19; CVID3; B4;

Function

Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens (PubMed:2463100, PubMed:1373518, PubMed:16672701).
Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca2+ stores (PubMed:9382888, PubMed:9317126, PubMed:12387743, PubMed:16672701).
Is not required for early steps during B cell differentiation in the blood marrow (PubMed:9317126).
Required for normal differentiation of B-1 cells (By similarity).
Required for normal B cell differentiation and proliferation in response to antigen challenges (PubMed:2463100, PubMed:1373518).
Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge (PubMed:9317126, PubMed:12387743, PubMed:16672701).

Biological Process

Antigen receptor-mediated signaling pathway Source: UniProtKB
B-1 B cell differentiation Source: Ensembl
B cell proliferation involved in immune response Source: UniProtKB
B cell receptor signaling pathway Source: UniProtKB
Immunoglobulin mediated immune response Source: UniProtKB
Positive regulation of phosphatidylinositol 3-kinase activity Source: UniProtKB
Positive regulation of protein kinase B signaling Source: Reactome
Positive regulation of release of sequestered calcium ion into cytosol Source: UniProtKB
Regulation of B cell activation Source: UniProtKB
Regulation of B cell receptor signaling pathway Source: UniProtKB
Regulation of complement activation Source: Reactome
Regulation of immune response Source: Reactome

Cellular Location

Cell membrane; Membrane raft

Involvement in disease

Immunodeficiency, common variable, 3 (CVID3): A primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low.

Topology

Extracellular: 20-291
Helical: 292-313
Cytoplasmic: 314-556

PTM

Phosphorylated on tyrosine following B-cell activation (PubMed:7684160, PubMed:7687539, PubMed:10706702, PubMed:12387743). Phosphorylated on tyrosine residues by LYN (PubMed:7687428). Tyrosine residues are phosphorylated sequentially after activation of the B cell receptor. Phosphorylation of Tyr-531 is extremely rapid, followed by phosphorylation at Tyr-409. In contrast, phosphorylation of Tyr-500 appears more slowly and is more transient, returning rapidly to basal levels (By similarity).

Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., ... & Miklos, D. B. (2021). CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine, 27(8), 1419-1431.

Nerreter, T., Letschert, S., Götz, R., Doose, S., Danhof, S., Einsele, H., ... & Hudecek, M. (2019). Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T. Nature communications, 10(1), 1-11.

Ying, Z., Huang, X. F., Xiang, X., Liu, Y., Kang, X., Song, Y., ... & Chen, S. Y. (2019). A safe and potent anti-CD19 CAR T cell therapy. Nature medicine, 25(6), 947-953.

Hatterer, E., Barba, L., Noraz, N., Daubeuf, B., Aubry-Lachainaye, J. P., von der Weid, B., ... & Buatois, V. (2019, February). Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation. In MAbs (Vol. 11, No. 2, pp. 322-334). Taylor & Francis.

Salter, A. I., Pont, M. J., & Riddell, S. R. (2018). Chimeric antigen receptor–modified T cells: CD19 and the road beyond. Blood, The Journal of the American Society of Hematology, 131(24), 2621-2629.

Bagashev, A., Sotillo, E., Tang, C. H. A., Black, K. L., Perazzelli, J., Seeholzer, S. H., ... & Thomas-Tikhonenko, A. (2018). CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum. Molecular and cellular biology, 38(21), e00383-18.

Turtle, C. J., Hay, K. A., Hanafi, L. A., Li, D., Cherian, S., Chen, X., ... & Maloney, D. G. (2017). Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor–modified T cells after failure of ibrutinib. Journal of Clinical Oncology, 35(26), 3010.

Alabanza, L., Pegues, M., Geldres, C., Shi, V., Wiltzius, J. J., Sievers, S. A., ... & Kochenderfer, J. N. (2017). Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Molecular Therapy, 25(11), 2452-2465.

Li, X., Ding, Y., Zi, M., Sun, L., Zhang, W., Chen, S., & Xu, Y. (2017). CD19, from bench to bedside. Immunology letters, 183, 86-95.

Liu, L., Lam, C. Y. K., Long, V., Widjaja, L., Yang, Y., Li, H., ... & Bonvini, E. (2017). MGD011, A CD19 x CD3 dual-affinity retargeting bi-specific molecule incorporating extended circulating half-life for the treatment of B-cell malignancies. Clinical Cancer Research, 23(6), 1506-1518.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-CD19 Recombinant Antibody (CBXC-1224)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Antibody Pairs

CD19 Matched Antibody Pair (207) (CAT#: APMAB-207LY)

CD19 Matched Antibody Pair (208) (CAT#: APMAB-208LY)

Related Products

CD19 Matched Antibody Pair (208) (CAT#: APMAB-208LY)

Mouse Anti-CD19 Recombinant Antibody (PDR134) (CAT#: CBMAB-C0982-CQ)

Mouse Anti-CD19 Recombinant Antibody (CBT281) (CAT#: V2LY-0625-LY3638)

CD19 Matched Antibody Pair (207) (CAT#: APMAB-207LY)

Mouse Anti-CD19 Recombinant Antibody (HIB19) (CAT#: CBMAB-C0706-CQ)

Mouse Anti-CD19 Recombinant Antibody (CBT280) (CAT#: V2LY-0625-LY3639)

Mouse Anti-CD19 Recombinant Antibody (CBYJL-063) (CAT#: CBMAB-L0115-YJ)

Mouse Anti-CD19 Recombinant Antibody (CBT4765) (CAT#: V2LY-0625-LY2093)

Mouse Anti-CD19 Recombinant Antibody (SJ25-C1) (CAT#: CBMAB-C1034-CQ)

Rabbit Anti-CD19 Recombinant Antibody (109) (CAT#: CBMAB-C2084-LY)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry